[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-372616-105":59,"doc-detail-372616-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","melanoma-update-is-a-cure-now-in-sight","Melanoma update: is a cure now in sight?","","Melanoma, one of the most aggressive skin cancers, creates a major global health burden due to its high metastatic risk and resistance to traditional therapies. This review summarizes recent advances in melanoma treatment, focusing on targeted therapies and immunotherapies that have improved survival and quality of life for advanced disease. It highlights combination and sequential approaches, including immune checkpoint inhibitors, cancer vaccines, BRAF mutation-targeted strategies, and emerging work on tumour-infiltrating lymphocytes, oncolytic viruses, and personalised vaccines. Persistent challenges include drug resistance and the need for reliable biomarkers to predict response and guide patient selection, while clinical trials aim to refine treatment and move toward cure.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/melanoma-update-is-a-cure-now-in-sight/372616/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/melanoma-update-is-a-cure-now-in-sight/372616.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is melanoma considered difficult to cure with conventional treatments?","Question",{"text":112,"@type":113},"Melanoma is aggressive, often metastasizes, and shows resistance to conventional therapies, which have historically produced limited response rates and substantial toxicity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How have immunotherapy and BRAF/MEK inhibitors changed outcomes in advanced melanoma?",{"text":117,"@type":113},"Over the past decade, immune checkpoint inhibitors and BRAF/MEK inhibitors have transformed outcomes, with some long-term survival patterns suggesting the possibility of cure in selected patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What key obstacles remain despite recent therapeutic progress?",{"text":121,"@type":113},"Drug resistance limits durable benefit, and reliable biomarkers are still needed to predict treatment response and select appropriate patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},372616,1790217236,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","| \u003Cbr>| \u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>|\n| --- | --- |\n|  |  |\n\ndoi:10.1111/imj.70085  \nCLINICAL PERSPECTIVE  \nMelanoma update: is a cure now in sight? Samrin Liaqat  and Muhammad Adnan Khattak  \nDepartment of Medical Oncology, Fiona Stanley Hospital, Perth, Western Australia, Australia  \nKey words  \nmelanoma, immunotherapy, targeted therapy, tumour-infiltrating lymphocyte, cancer vaccine.  \nCorrespondence  \nMuhammad Adnan Khattak, Department of Medical Oncology, Fiona Stanley Hospital, 11 Robin Warren Drive, Murdoch,  \nWA 6150, Australia. [Email:](Email: muhammad.khattak@health.wa.gov.au)[ muhammad.khattak@health.wa.gov.au](Email: muhammad.khattak@health.wa.gov.au)  \nReceived 6 December 2024; accepted  \n7 April 2025 .  \nAbstract  \nMelanoma, one of the most aggressive skin cancers, poses a significant global health concern due to its high metastatic potential and resistance to conventional treatments. This review explores recent advancements in melanoma treatment, particularly the impact of targeted therapies and immunotherapies which have significantly extended survival and improved the quality of life for advanced melanoma patients. Additionally, the innovative combination and sequential strategies, with immune checkpoint inhibitors and cancer vaccines or targeted therapies against BRAF mutations, mark a promising direction. Recent advances in tumour infiltrating lymphocytes and oncolytic virus therapy and personalised cancer vaccine development are also covered, highlighting the role of precision medicine in achieving tailored, effective treatments. Despite these advancements, challenges persist, including drug resistance and the need for reliable biomarkers to predict treatment response and select patients. This review underscores the ongoing efforts in research and clinical trials to refine therapeutic strategies, improve treatment outcomes for a larger population detection and, ultimately, advance towards a cure for melanoma.  \nIntroduction  \nMelanoma represents a major public health concern in Australia, ranking as the third most prevalent cancer and the 11th leading cause of cancer-related mortality.1 Approximately a decade ago, advanced melanoma was regarded as a highly lethal cutaneous malignancy, with a median overall survival (OS) of merely 6–8 months.2 Atthe time, treatment strategies primarily relied on cytotoxic chemotherapy agents such as dacarbazine or cytokines like interleukin-2 (IL-2) and interferon. However, these approaches yielded poor outcomes, with limited response rates and considerable toxicity.3 Even for patients with localised disease, relapse and systemic dissemination following surgical resection posed significant challenges, as adjuvant treatments available at the time were suboptimal for achieving a definitive cure.  \nIn the early 21st century, groundbreaking advancements in molecular biology, cancer genomics, immunology and drug development transformed the treatment landscape for melanoma, bringing renewed hope to  \nFunding: None.  \nConflict of interest: None.  \npatients. Today, with modern therapeutic strategies, nearly 50% of patients with metastatic melanoma achieve durable, long-term remission exceeding 5 years, raising the possibility of a potential cure.4 As survival rates continue to improve, one pressing question emerges: Could a cure for melanoma finally be within our grasp?  \nThis article delves into recent advancements in melanoma treatment, highlighting the potential for achieving long-term remissions and exploring emerging therapeutic approaches. Although not comprehensive, it offers a valuable overview of the key developments in this rapidly evolving field.  \nMetastatic melanoma  \nThe introduction of immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors over the past decade has significantly transformed outcomes for patients with advanced melanoma. Once considered a highly lethal disease, with fewer than 10% of patients surviving beyond 5 years, melanoma may now be cu","cbCaiadP02wnP8Nd","https://ap.wps.com/l/cbCaiadP02wnP8Nd","pdf",662142,"English","# Introduction\n# Metastatic melanoma\n# Immune checkpoint inhibitors","[{\"question\":\"Why is melanoma considered difficult to cure with conventional treatments?\",\"answer\":\"Melanoma is aggressive, often metastasizes, and shows resistance to conventional therapies, which have historically produced limited response rates and substantial toxicity.\"},{\"question\":\"How have immunotherapy and BRAF/MEK inhibitors changed outcomes in advanced melanoma?\",\"answer\":\"Over the past decade, immune checkpoint inhibitors and BRAF/MEK inhibitors have transformed outcomes, with some long-term survival patterns suggesting the possibility of cure in selected patients.\"},{\"question\":\"What key obstacles remain despite recent therapeutic progress?\",\"answer\":\"Drug resistance limits durable benefit, and reliable biomarkers are still needed to predict treatment response and select appropriate patients.\"}]","Melanoma update: is a cure now in sight? | PDF",1790194953,23]